Log in with your email address username.


[Comment] Aspirin—still the GLOBAL LEADER in antiplatelet therapy

Dual antiplatelet therapy for at least a year is the standard of care after an acute coronary syndrome. Attempts to shorten the duration of therapy have resulted in an increase in myocardial infarction.1,2 Lengthening of the duration of dual antiplatelet therapy beyond a year in high-risk patients with acute coronary syndromes further reduces the risk of myocardial infarction and even ischaemic stroke.3 In patients undergoing elective percutaneous coronary intervention with current-generation drug-eluting stents, treatment guidelines recommend 6 months of dual antiplatelet therapy (or potentially longer if complex stenting is necessary).